BioCentury | Aug 30, 2018
Targets & Mechanisms


Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
BioCentury | Aug 22, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

...mice suggest activating MRAP2 could help treat obesity. In mice, heterozygous or homozygous deletion of Mrap2...
...increased obesity and visceral adiposity compared with no deletion. In human samples, rare mutations in MRAP2...
...obese individuals but not in controls. Next steps could include understanding the mechanism by which MRAP2...
BioCentury | Oct 26, 2009
Product Development

Breaking through the BBB

The idea of using the brain's own transport receptors to ferry drugs across the blood-brain barrier has been around for more than a decade. AngioChem Inc. , one of a new generation of companies trying to...
BioCentury | Aug 31, 2009
Emerging Company Profile

Heat Biologics: Shocking exposure

Heat Biologics Inc. believes that its heat shock protein technology for cancer immunotherapy may have an advantage over competitors because it exposes the immune system to all of a cancer's antigens, whereas other treatments only...
Items per page:
1 - 4 of 4